Clinical trial
Study for The Prevention Of Nausea in Cancer Patients Receiving Highly…
NCT00169572 · GlaxoSmithKline, Industry · Completed
Key facts
| NCT number | NCT00169572 |
|---|---|
| Title | Study for The Prevention Of Nausea in Cancer Patients Receiving Highly Emetogenic Cisplatin Based Chemotherapy |
| Official title | See Detailed Description |
| Lead sponsor | GlaxoSmithKline, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Nausea and Vomiting, Chemotherapy-Induced |
| Intervention type | Drug |
| Interventions | Aprepitant, Ondansetron, GW679769, Dexamethasone |
| Enrollment | 492 |
| Start date | Feb 1, 2005 |
| First posted | Sep 15, 2005 |
| Last update posted | May 10, 2010 |
| Countries | Argentina, Austria, Belgium, Chile, Croatia, Czechia, Hong Kong, Hungary, Italy, Mexico, Netherlands, Pakistan and 7 more |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: